Celularity Analyst Ratings
Celularity Analyst Ratings
While ratings are subjective and will change, the latest Celularity (CELU) rating was a maintained with a price target of $8.00 to $5.00. The current price Celularity (CELU) is trading at is $2.46, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/12/2022 | 103.25% | Morgan Stanley | $8 → $5 | Maintains | Equal-Weight |
| 08/25/2022 | 509.76% | Alliance Global Partners | → $15 | Initiates Coverage On | → Buy |
| 08/23/2022 | 143.9% | Truist Securities | $10 → $6 | Maintains | Hold |
| 06/22/2022 | 509.76% | HC Wainwright & Co. | → $15 | Initiates Coverage On | → Buy |
| 04/06/2022 | — | Truist Securities | Downgrades | Buy → Hold | |
| 01/28/2022 | 265.85% | Oppenheimer | → $9 | Initiates Coverage On | → Outperform |
| 11/24/2021 | 265.85% | Morgan Stanley | → $9 | Initiates Coverage On | → Equal-Weight |
| 10/19/2021 | 387.8% | Truist Securities | → $12 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析師事務所 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 09/12/2022 | 103.25% | 摩根士丹利 | 8 美元 → 5 美元 | 維護 | 等重 |
| 08/25/2022 | 509.76% | 聯盟全球合作伙伴 | → 15 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2022 年 8 月 23 日 | 143.9% | Truist 證券 | 10 美元 → 6 美元 | 維護 | 保持 |
| 06/22/2022 | 509.76% | HC Wainwright & Co. | → 15 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 04/06/2022 | — | Truist 證券 | 降級 | 買入 → 持有 | |
| 01/28/2022 | 265.85% | 奧本海默 | → 9 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 11/24/2021 | 265.85% | 摩根士丹利 | → 9 美元 | 啓動覆蓋範圍開啓 | → 重量相等 |
| 10/19/2021 | 387.8% | Truist 證券 | → 12 美元 | 啓動覆蓋範圍開啓 | → 購買 |
Celularity Questions & Answers
Cellarity 問題與解答
The latest price target for Celularity (NASDAQ: CELU) was reported by Morgan Stanley on September 12, 2022. The analyst firm set a price target for $5.00 expecting CELU to rise to within 12 months (a possible 103.25% upside). 8 analyst firms have reported ratings in the last year.
摩根士丹利於2022年9月12日公佈了Celularity（納斯達克股票代碼：CELU）的最新目標股價。該分析公司將目標股價設定爲5.00美元，預計CELU將在12個月內上漲至5美元（可能上漲103.25％）。去年有8家分析公司公佈了評級。
The latest analyst rating for Celularity (NASDAQ: CELU) was provided by Morgan Stanley, and Celularity maintained their equal-weight rating.
Celularity（納斯達克股票代碼：CELU）的最新分析師評級由摩根士丹利提供，Celularity維持同等權重評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Celularity, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Celularity was filed on September 12, 2022 so you should expect the next rating to be made available sometime around September 12, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Celularity的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。Celularity的最後一次評級是在2022年9月12日提交的，因此您應該預計下一個評級將在2023年9月12日左右公佈。
While ratings are subjective and will change, the latest Celularity (CELU) rating was a maintained with a price target of $8.00 to $5.00. The current price Celularity (CELU) is trading at is $2.46, which is out of the analyst's predicted range.
儘管評級是主觀的，並將發生變化，但最新的Celularity（CELU）評級維持不變，目標股價爲8.00美元至5.00美元。Celularity（CELU）目前的交易價格爲2.46美元，超出了分析師的預測區間。
